Furthermore, knockdown of SALL4 can restore cisplatin sensitivity in acquired resistant lung cancer cells via the AKT/mTOR signaling pathway [46], and the antineoplastic drug entinostat can target SALL4-positive lung cancer [133]. Here, MTOR is linked to lung cancer.